Key Segments:
By Product & Services
-
Reagents and Media
-
Equipment
-
Accessories and Consumables
-
Services
By Source
-
Mammalian Cell Line
-
Non-mammalian Cell Line
By Type of Cell Line
-
Recombinant Cell Lines
-
Hybridomas
-
Continuous Cell Lines
-
Primary Cell Lines
By Application
-
Bioproduction
-
Drug Discovery
-
Toxicity Testing
-
Tissue Engineering
-
Others
Regional Coverage:
North America
-
US
-
Canada
Europe
-
Germany
-
France
-
UK
-
Italy
-
Spain
-
Poland
-
Russia
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
Key players include Thermo Fisher Scientific Inc., Lonza Group AG, Sartorius AG, Danaher Corporation, Merck KGaA, and Samsung Biologics Co., Ltd., among other biopharmaceutical technology providers.
Continued advancement of genome editing technology and continued expansion of contract development and manufacturing capacity represent the primary opportunities for providers.
Growth is primarily driven by rising demand for biologic drugs and biosimilars, combined with increasing prevalence of cancer and an ageing global population.
By Product & Service Type, Reagents & Media dominated the market with in 2025.
North America dominated the market with a 41.60% share in 2025, supported by advanced healthcare infrastructure and strong adoption of innovative biologics.
